Navigation Links
LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available
Date:11/16/2009

diopulmonary resuscitation must be immediately available.

The following serious adverse reactions have been reported with the use of LUSEDRA.

  • Respiratory depression
    • Apnea was reported in 1/455 (< 1%) patients treated with LUSEDRA using the standard or modified dosing regimen.
  • Hypoxemia
    • Hypoxemia was reported in 20/455 (4%) patients treated with LUSEDRA using the standard or modified dosing regimen. Retention of purposeful responsiveness did not prevent patients from becoming hypoxemic following administration of LUSEDRA.
  • Loss of purposeful responsiveness
    • LUSEDRA has not been studied for use in general anesthesia. However, administration of LUSEDRA may inadvertently cause patients to become unresponsive or minimally responsive to vigorous tactile or painful stimulation. The incidence of patients who became minimally responsive or unresponsive to vigorous tactile or painful stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for bronchoscopy. The duration of minimal or complete unresponsiveness ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20 minutes in bronchoscopy patients.
  • Hypotension
    • Hypotension was reported in 18/455 (4%) patients treated with LUSEDRA using the standard or modified dosing regimen.
    • Patients with compromised myocardial function, reduced vascular tone, or who have reduced intravascular volume may be at an increased risk for hypotension.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. LUSEDRA may produce additive cardiorespiratory effects when administered with other cardiorespiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

'/>"/>
SOURCE Eisai Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
2. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
7. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
8. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
(Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
(Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
(Date:10/30/2014)... October 30, 2014 The human brain ... more vigorously exercised to help maintain better mental health, ... book ‘Dementia Express: Lose Your Memory in 100 Ways’ ... reasoning and sometimes conflicting attitudes to help keep the ... mind, a reader must decipher the hidden logic within. ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, ... time they wonder, “Should I use an answering service?” The ... through a series of yes or no questions that ultimately ... are many considerations and scenarios that come into play when ... . This decision infographic serves as a bit of a ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... common plastics, chemical during pregnancy may have effects on genital ... found that baby boys born to moms with greater exposure ... anogenital distance -- the space between the genitals and anus. ... a marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... 2014 (HealthDay News) -- Eating a low-carb, high-fat diet ... according to new research. A review of ... diet, that focuses on foods like bacon, eggs, heavy ... seizures in adults whose condition doesn,t improve with medication. ... of people with epilepsy whose seizures are not stopped ...
Breaking Medicine News(10 mins):Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... Healthcare ( www.siemens.com/healthcare ) ... the Workflow & Solutions Division, Siemens Healthcare, testified before the ... Representatives on the need for healthcare reform. ... ) , , During the hearing, "Comprehensive Health ...
... , Supporting individual quality of life and American business ... 24 The U.S. Women,s Chamber of Commerce submitted ... to restore American values and business competitiveness through the ... report include the support of Health Insurance Exchanges, guaranteed ...
... Inc. (NYSE: WPI ), a leading specialty ... Inc., has received approval today from the United States ... Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women ... equivalent to Duramed Pharmaceuticals, PLAN B(R), which is indicated ...
... memories , WEDNESDAY, June 24 (HealthDay News) -- Researchers ... long-term storage of memories. , Their study showed that ... remember them less well than mice who can perform ... Circuit Genetics at MITs Picower Institute for Learning and ...
... shows better survival when compared to those who ... News) -- A new Canadian study adds compelling ... get clot-dissolving treatment for heart attacks should have ... "This study strengthens the guideline recommendations," said Dr. ...
... Mich., June 24 Validation and Compliance Institute (VCI), ... FDA regulated industries, will offer a series of Dietary ... (DBA), a division of NSF International. , ... the new GMP regulations for dietary supplements, which the ...
Cached Medicine News:Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3Health News:U.S. Women's Chamber of Commerce Advocates Strong Healthcare Reforms in Support of American Values 2Health News:Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R) 2Health News:Sleep May Be Essential for Long-Term Memory 2Health News:Quick Angioplasty Best After Heart Attacks 2Health News:Quick Angioplasty Best After Heart Attacks 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: